Journal of Clinical Oncology
Articles in this Issue
Update of the EORTC QLQ-Ovarian Cancer Module (EORTC-QLQ-OV28) phase I and II.
5596 Background: Ovarian cancer is the eighth most common cancer in women worldwide. The 5-year survival rate is 90.0% for...
Impact of baseline demographics on therapy management in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with talazoparib (TALA) + enzalutamide (ENZA) in the TALAPRO-2 study: Extended follow-up.
5043 Background: The randomized, Phase 3 TALAPRO-2 trial showed improved radiographic progression-free survival (rPFS) and...
Integrating artificial intelligence to evaluate outcomes and disparities in young-onset breast cancer: A SEER-based retrospective cohort study.
1029 Background: Young-onset breast cancer (YOBC), defined as breast cancer diagnosed in women <40 years, is associated...
Perioperative or adjuvant PD-1/PD-L1 blockade with curative-intent multimodality therapy for locally advanced head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized trials.
e18074 Background: Multiple phase III trials have evaluated the addition of perioperative or adjuvant/postoperative PD-1/P...
Real-world evidence of pembrolizumab efficacy and safety in patients with NSCLC with high PD-L1 expression.
e20620 Background: Immune check-point inhibitors improved survival in patients with NSCLC and no driver mutations. Pembrol...
Lineage-specific outcomes and resource utilization associated with antiphospholipid syndrome and thrombotic microangiopathy phenotypes during U.S. cancer hospitalizations: National Inpatient Sample, 2018–2022.
e19110 Background: Antiphospholipid syndrome (APS) and thrombotic microangiopathy (TMA) phenotypes are rare, high-acuity t...
Neoadjuvant targeted therapy versus chemoimmunotherapy in lung adenocarcinoma: A dual-center comparative study of surgical and survival outcomes.
e20071 Background: Although neoadjuvant chemoimmunotherapy (NCI) and targeted therapy (NTT) represent primary therapeutic...
Elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor, as first-line therapy for <i>KRAS</i> G12C mutation–positive non–small cell lung cancer (NSCLC).
8511 Background: Elisrasib (D3S-001) is a next-generation KRAS G12C inhibitor (G12Ci) designed to improve target engagemen...
Liquid biopsy at the finish line: End-of-treatment ctDNA predicts relapse and survival in diffuse large B-cell lymphoma.
e19116 Background: PET/CT is the primary end-of-treatment (EOT) evaluation for diffuse large B-cell lymphoma (DLBCL); yet,...
A generative model–assisted clinical decision support system for the postoperative management of colon cancer.
e15508 Background: Postoperative management of colon cancer relies on the accurate interpretation of complex pathology rep...
Sepsis risk factors and associated mortality in elderly mesothelioma patients with malignant pleural effusion.
e20063 Background: Age is an independent prognostic factor worse outcomes in mesothelioma patients. A significant proporti...
Gamma knife radiosurgery for brain metastases in the era of modern systemic therapy: A prospective real-world analysis using disease-specific GPA and RANO-BM.
e14026 Background: Gamma Knife radiosurgery (GKRS) is widely used for local control of brain metastases (BM), yet prospect...
Prognostic and predictive value of circulating tumor cells (CTC) phenotypes in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial.
e15065 Background: CTCs are a minimally invasive biomarkers in metastatic colorectal/appendiceal cancer, however, standard...
Prediction of axillary response in 5,262 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study.
505 Background: Axillary lymph node dissection (ALND) for node-positive breast cancer (BC) converting to clinical node-neg...
Impact of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) on outcomes in hepatocellular carcinoma treated with atezolizumab–bevacizumab.
4117 Background: Immune checkpoint inhibitor–based combinations (ICIs), including atezolizumab–bevacizumab (AB), have dram...
Assessing the impact of PCSK9 inhibition in small cell lung cancer with novel DLL3-targeted bispecific T-cell engager therapy.
e20135 Background: B-specific T-cell engagers (BiTEs) such as tarlatamab, have improved upon the efficacy and durability o...
PEAK-1: A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma.
TPS4636 Background: For patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have relaps...
Association of steroid exposure with overall survival and hypersensitivity reaction risk in paclitaxel-treated patients with gynecologic cancers.
5541 Background: Paclitaxel remains a first-line agent in chemotherapy regimens for gynecologic cancers but is associated...
Fear of cancer recurrence in oncology follow-up: Prevalence and the role of patient–oncologist communication.
e24101 Background: Fear of cancer recurrence (FCR) is one of the most frequent and least addressed concerns among patients...
Tumor-type–stratified causal machine learning to identify heterogeneous benefit of PD-(L)1+CTLA-4 versus PD-(L)1 monotherapy: A hypothesis-generating analysis from the MSK pan-cancer cohort.
e14505 Background: Combination immune checkpoint inhibition (ICI) can improve survival but increases immune-related advers...
A four-marker-protein signature to predict ramucirumab efficacy in combination with TAS-102 in advanced colorectal cancer: Translational analysis of the RAMTAS trial of the German AIO (AIO-KRK-0316/IKF643).
3588 Background: The combination of TAS-102 and bevacizumab is standard in the treatment of advanced colorectal cancer (aC...
Global burden of disease analysis of acute lymphoblastic leukemia in children in Africa: Incidence, prevalence, and DALYs (1990–2023).
e18620 Background: Hematological malignancies, including leukemia, lymphoma, and multiple myeloma, contribute significantl...
Characteristics of cancer drug-indication pairs recommended for funding on the Australian Pharmaceutical Benefits Scheme (PBS), 2005-2025.
e23039 Background: The cost of cancer drugs is substantial and increasing, intensifying scrutiny of regulatory and health...
Clinical impact of GLP-1 receptor agonist use on lung cancer incidence in high-risk patients: A real-world analysis.
10559 Background: Lung cancer (LC) is the leading cause of cancer-related mortality in the United States. Lifetime risk is...
Clinicopathological spectrum and HER2/MSI biomarker status in gastric adenocarcinoma: A tertiary care retrospective cohort from Pakistan.
e16084 Background: Gastric cancer (GC) is a leading cause of cancer mortality in Pakistan, where delayed diagnosis, limite...